Amplyx’s first-in-class antifungal heads for a head-to-head study

Following a positive Phase II readout, Amplyx plans to take lead candidate fosmanogepix into a Phase III head-to-head trial against echinocandins as first-line treatment for invasive Candida infections.

Echinocandins are standard of care in the indication, but resistance to the class is a growing concern...